incretin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-15. Numbers and descriptions here follow the published literature rather than marketing material.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Denny (Denisova 11) is an ~90,000 year old fossil specimen belonging to a ~13-year-old Neanderthal-Denisovan hybrid girl. To date, she is the only first-generation hybrid hominin ever discovered. Denny's remains consist of a single fossilized fragment of a long bone discovered among over 2,000 visually unidentifiable fragments excavated at the Denisova Cave in the Altai Mountains, Russia in 2012. A team of researchers at Oxford University led by Tom Higham used a method of collagen peptide mass fingerprinting, called Zooarchaeology by Mass Spectrometry (ZooMS), and mitochondrial DNA (mtDNA) analysis to identify the fragment as belonging to an archaic human with Neanderthal ancestry. Genomic sequencing and analysis led by paleo-geneticists Viviane Slon and Svante Pääbo of the Max Planck Institute for Evolutionary Anthropology revealed that Denny was the offspring of a Neanderthal mother and a Denisovan father. Additionally, her genome suggests that her father also carried a small degree of Neanderthal ancestry from 300 to 600 generations prior to his lifetime. These surprising genomic data have caused some paleontologists to speculate that interspecies mating between Denisovans and Neanderthals could have occurred with some frequency during several periods of contact over many thousands of years. Additionally, these findings lend support to the hypothesis that similar patterns of admixture, or interbreeding between archaic and modern humans, may have resulted in the partial absorption of Denisovans and Neanderthals into modern human populations.
=== Names === Amitriptyline is the English and French generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française, while amitriptyline hydrochloride is its USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name. Its generic name in Spanish and Italian and its DCITTooltip Denominazione Comune Italiana are amitriptilina, in German is Amitriptylin, and in Latin is amitriptylinum. The embonate salt is known as amitriptyline embonate, which is its BANM, or as amitriptyline pamoate unofficially. Other brand names include Elavil, Vanatrip, Endep and Tryptomer.
=== Economics === In December 2019, the US FDA approved a generic version of apixaban produced jointly by Mylan and Micro Labs. BMS and Pfizer worked quickly to block generics from being created, and in August 2020, they won a patent infringement lawsuit against Sigmapharm, Sunshine Lake, and Unichem, after previously settling patent cases against 25 other companies. In September 2021, a Federal Circuit Court upheld the ruling. The result is that apixaban generics will most likely not be available in the United States until at least 2026, but possibly 2031. In July 2022, the Canadian generic drug company, Apotex Inc., obtained approval for marketing of apixaban. Pfizer reported revenue of US$6.747 billion for Eliquis in 2023. Apixaban is one of ten medications covered by price negotiations in the US under the Inflation Reduction Act. The negotiations, conducted by the Centers for Medicare & Medicaid Services, apply to pricing for Medicare recipients. The results of the negotiations were announced in August 2024, and Medicare's negotiated price for a 30-day supply of Eliquis is $231, a 56% decrease from the 2023 list price of $521. The pricing is set to take effect in 2026.
Sources: en.wikipedia.org
In organic chemistry, thioesters are organosulfur compounds with the molecular structure R−C(=O)−S−R'. They are analogous to carboxylate esters (R−C(=O)−O−R') with the sulfur in the thioester replacing oxygen in the carboxylate ester, as implied by the thio- prefix. They are the product of esterification of a carboxylic acid (R−C(=O)−O−H) with a thiol (R'−S−H). In biochemistry, the best-known thioesters are derivatives of coenzyme A, e.g., acetyl-CoA. The R and R' represent organyl groups, or H in the case of R.
=== Pharmacodynamics === Baclofen produces its effects by selectively activating the GABAB receptor. Baclofen is postulated to block mono-and-polysynaptic reflexes by acting as an inhibitory ligand, inhibiting the release of excitatory neurotransmitters. Baclofen does not have significant affinity for the GHB receptor, and has no known abuse potential. Agonism of GABAB receptors is thought to be responsible for baclofen's range of therapeutic properties, as GABAB knockout mice are unresponsive to the neurobiological effects of baclofen. For drug-reward and addiction, baclofen's mechanism of action is thought to be through its effect on the mesolimbic dopamine pathway, specifically leading to a decrease in dopamine release associated with alcohol. GABAB receptor activation (GABAB receptor agonist activity) may decrease or inhibit alcohol's ability to activate or fire dopaminergic neurons following exposure to alcohol. Baclofen's mechanism of action when used to treat alcohol use disorder is not thought to be mediated through its muscle-relaxing or sedative properties, however there is evidence to suggest that the GABAB receptor-activation in the limbus may also reduce feelings of anxiety in people with alcohol use disorder.
Messenger ribonucleic acid (mRNA) is a single-stranded molecule of RNA that corresponds to the genetic sequence of a gene, and is read by a ribosome in the process of synthesizing a protein. mRNA is created during the process of transcription, where an enzyme (RNA polymerase) converts the gene into primary transcript mRNA (also known as pre-mRNA). This pre-mRNA usually still contains introns, regions that will not go on to code for the final amino acid sequence. These are removed in the process of RNA splicing, leaving only exons, regions that will encode the protein. This exon sequence constitutes mature mRNA. Mature mRNA is then read by the ribosome, and the ribosome creates the protein utilizing amino acids carried by transfer RNA (tRNA). This process is known as translation. All of these processes form part of the central dogma of molecular biology, which describes the flow of genetic information in a biological system. As in DNA, genetic information in mRNA is contained in the sequence of nucleotides, which are arranged into codons consisting of three ribonucleotides each. Each codon codes for a specific amino acid, except the stop codons, which terminate protein synthesis. The translation of codons into amino acids requires two other types of RNA: transfer RNA, which recognizes the codon and provides the corresponding amino acid, and ribosomal RNA (rRNA), the central component of the ribosome's protein-manufacturing machinery. The concept of mRNA was first conceived by Sydney Brenner and Francis Crick in 1960 during a conversation with François Jacob.
Sources: en.wikipedia.org
=== Zeolitic imidazolate frameworks (ZIFs) === Several different mechanical phenomena have been observed in zeolitic imidazolate frameworks (ZIFs), the most widely studied MOF for mechanical properties due to their many similarities to zeolites. General trends for the ZIF family are the tendency of the Young's modulus and hardness of the ZIFs to decrease as the accessible pore volume increases. The bulk moduli of ZIF-62 series increase with the increasing of benzoimidazolate (bim−) concentration. ZIF-62 shows a continuous phase transition from open pore (op) to close pore (cp) phase when bim− concentration is over 0.35 per formular unit. The accessible pore size and volume of ZIF-62-bim0.35 can be precisely tuned by applying adequate pressures. Another study has shown that under hydrostatic loading in solvent the ZIF-8 material expands as opposed to contracting. This is a result of hyperfilling of the internal pores with solvent. A computational study demonstrated that ZIF-4 and ZIF-8 materials undergo a shear softening mechanism with amorphizing (at ~ 0.34 GPa) of the material under hydrostatic loading, while still possessing a bulk modulus on the order of 6.5 GPa. Additionally, the ZIF-4 and ZIF-8 MOFs are subject to many pressure dependent phase transitions.
=== Other bodies in exile === Other Grand Lodges were created for the Cuban exile community, including the United Grand Lodge of the Antilles (Spanish: Gran Logia Unida de las Antillas), and the Most Serene Grand Lodge (Spanish: Serenisima Gran Logia), and the Cuba First Federation of Cuban Masons in Exile (Spanish: Federacion de Masones Cubanos Cuba Primero).
=== Disinfection === Secretions from maggots believed to have broad-spectrum antimicrobial activity include allantoin, urea, phenylacetic acid, phenylacetaldehyde, calcium carbonate, proteolytic enzymes, and many others. In vitro studies have shown that maggots inhibit and destroy a wide range of pathogenic bacteria including methicillin-resistant Staphylococcus aureus (MRSA), group A and B streptococci, and Gram-positive aerobic and anaerobic strains. Other bacteria like Pseudomonas aeruginosa, E. coli or Proteus spp. are not attacked by maggots, and in case of Pseudomonas even the maggots are in danger.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.